Cure My Disease

Don't miss your cure!

 Log in / Sign up

CBD shows promise for Hard-to-Treat psychosis in major new trial

NCT ID NCT06778564

Not yet recruiting Symptom relief Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding cannabidiol (CBD) to standard antipsychotic medication can improve symptoms in people experiencing their first episode of psychosis who haven't responded well to initial treatment. About 250 participants aged 16-40 will receive either CBD or a placebo for 6 weeks, alongside their usual medication. The goal is to see if CBD can enhance treatment response and confirm its safety in this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FIRST EPISODE PSYCHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders schizoaffective disorder schizophrenia schizophreniform disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST EPISODE PSYCHOSIS PSYCHOSIS PSYCHOTIC DISORDERS PSYCHOTIC EPISODE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Cambridgeshire and Peterborough NHS Foundation Trust

    Cambridge, United Kingdom

  • Charité Universitätsmedizin

    Berlin, Germany

  • Geha Mental Health Center

    Petah Tikva, Israel

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Ludwig-Maximilian-University Munich

    Munich, Germany

  • MedUni Vienna

    Vienna, Austria

  • National and Kapodistrian University of Athens

    Athens, Greece

  • Oxford Health NHS Foundation Trust

    Oxford, United Kingdom

  • Psychiatric University Hospital (PUK), Zurich

    Zurich, Switzerland

  • Shalvata Mental Health Center

    Hod HaSharon, Israel

  • Sheba Medical Centre

    Ramat Gan, Israel

  • Stichting Amsterdam UMC

    Amsterdam, Netherlands

  • University Hospital Cologne

    Cologne, Germany

  • University of Augsburg

    Augsburg, Germany

  • University of Campania 'Luigi Vanvitelli'

    Naples, Italy

  • West London NHS Trust

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.